CC Coupling of Ketones with Methanol Catalyzed by a N-Heterocyclic Carbene-Phosphine Iridium Complex
作者:Xu Quan、Sutthichat Kerdphon、Pher G. Andersson
DOI:10.1002/chem.201405990
日期:2015.2.23
carbene–phosphine iridium complex system was found to be a very efficient catalyst for the methylation of ketone via a hydrogen transfer reaction. Mild conditions together with low catalyst loading (1 mol %) were used for a tandem process which involves the dehydrogenation of methanol, CC bond formation with a ketone, and hydrogenation of the new generated double bond by iridium hydride to give the
Iron-Catalyzed Methylation Using the Borrowing Hydrogen Approach
作者:Kurt Polidano、Benjamin D. W. Allen、Jonathan M. J. Williams、Louis C. Morrill
DOI:10.1021/acscatal.8b02158
日期:2018.7.6
developed using methanol as a C1 building block. This borrowing hydrogen approach employs a Knölker-type (cyclopentadienone)ironcarbonyl complex as catalyst (2 mol %) and exhibits a broad reaction scope. A variety of ketones, indoles, oxindoles, amines, and sulfonamides undergo mono- or dimethylation in excellent isolated yields (>60 examples, 79% average yield).
Catalytic C<sub>1</sub>
Alkylation with Methanol and Isotope-Labeled Methanol
作者:Jan Sklyaruk、Jannik C. Borghs、Osama El-Sepelgy、Magnus Rueping
DOI:10.1002/anie.201810885
日期:2019.1.14
A metal‐catalyzed methylation process has been developed. By employing an air‐ and moisture‐stable manganese catalyst together with isotopically labeled methanol, a series of D‐, CD3‐, and 13C‐labeled products were obtained in good yields undermild reaction conditions with water as the only byproduct.
申请人:The United States of America, as Represented by the Secretary, Dept. of Health & Human Services
公开号:US20150119426A1
公开(公告)日:2015-04-30
Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R
1
, and R
2
are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.